A5069642807- Healthcare Policy and Management
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Economic Theory and Policy
- Global Health Care Issues
- Pharmaceutical Economics and Policy
- Organ Donation and Transplantation
- Prostate Cancer Diagnosis and Treatment
- Monetary Policy and Economic Impact
- Global Financial Crisis and Policies
- Healthcare cost, quality, practices
- Primary Care and Health Outcomes
- Economic theories and models
- Prostate Cancer Treatment and Research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Patient Satisfaction in Healthcare
- Antibiotic Use and Resistance
- Renal and Vascular Pathologies
- Organ Transplantation Techniques and Outcomes
- Palliative Care and End-of-Life Issues
- Renal Transplantation Outcomes and Treatments
- Healthcare Systems and Reforms
Emory University
2016-2025
Rutgers, The State University of New Jersey
2025
Rutgers New Jersey Medical School
2025
Tampa General Hospital
2024
University of South Florida
2024
Twitter (United States)
2024
Centers for Disease Control and Prevention
2014-2022
National Center for Chronic Disease Prevention and Health Promotion
2016-2022
Emory Healthcare
2016-2021
King's College London
2021
Obese people incur higher health care costs at a given point in time, but how rising obesity rates affect spending growth over time is unknown. We estimate obesity-attributable increases between 1987 and 2001. Increases the proportion of on obese relative to normal weight account for 27 percent rise inflation-adjusted per capita 2001; diabetes, 38 percent; hyperlipidemia, 22 heart disease, 41 percent. prevalence alone 12 spending.
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course therapy. The was associated with an incremental increase in life expectancy four months. Drugs like ipilimumab have fueled perception that launch prices new anticancer drugs and other so-called “specialty” pharmaceutical market been increasing over time increases are unrelated to magnitude expected health benefits. this paper, we discuss unique features assess...
Importance Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection indolent cancers resulting from the poor specificity PSA for high-grade PCa (ie, grade group [GG] 2 or greater). Objective To develop a multiplex urinary panel validate its external performance relative to current guideline-endorsed biomarkers. Design, Setting, Participants RNA sequencing analysis 58 724 genes identified 54 markers...
We examine the impact of rise in treated disease prevalence on growth Medicare beneficiaries' health care spending. Virtually all this spending is associated with patients who are under medical management for five or more conditions. This traced to both a true and changes clinical treatment thresholds. Using metabolic syndrome as case study, we find that share medications has increased 11.5 percentage points less than ten years. raises important questions about "fit" how pays services...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue
There has not been a comprehensive analysis of how aggregate cancer costs have changed over time. The authors present 1) updated estimates the prevalence and total cost for select payers these past 2 decades; 2) each payer, distribution payments by type service time to assess whether there shifts in treatment settings.Pooled data from 2001 through 2005 Medical Expenditure Panel Survey 1987 National Care were used analysis. an econometric approach estimate cancer-attributable medical...
The addition of bevacizumab to fluorouracil-based chemotherapy is a standard care for previously untreated metastatic colorectal cancer. Continuation beyond progression an accepted based on 1.4-month increase in median overall survival observed randomized trial. No United States-based cost-effectiveness modeling analyses are currently available addressing the use Our objective was determine cost effectiveness first-line setting and when continued from perspective US payers.
Before the 2014 implementation of a new kidney allocation system by United Network for Organ Sharing, white patients were more likely than black or Hispanic to receive transplant. To determine effect on these disparities, we examined data 179,071 transplant waiting list events in period June 2013–September 2016, and calculated monthly transplantation rates (34,133 actually received transplants). Implementation was associated with narrowing disparities average 0.29 percentage point blacks...
The impact of a new national kidney allocation system (KAS) on access to the deceased-donor waiting list (waitlisting) and racial/ethnic disparities in waitlisting among US end-stage renal disease (ESRD) patients is unknown. We examined pre- post-KAS incident (N = 1 253 100) prevalent 556 954) ESRD from United States Renal Data System database (2005-2015) using multivariable time-dependent Cox interrupted time-series models. adjusted rate was 9% lower (hazard ratio [HR]: 0.91; 95% confidence...
Employers may incur costs related to absenteeism among employees who have chronic diseases or unhealthy behaviors. We examined the association between employee and 5 conditions: 3 risk factors (smoking, physical inactivity, obesity) 2 (hypertension diabetes).We identified from data sources: MarketScan Health Risk Assessment Medical Expenditure Panel Survey (MEPS). Absenteeism was measured as number of workdays missed because sickness injury. used zero-inflated Poisson regression estimate...
<h3>Objective:</h3> To quantify the socioeconomic burden of frontotemporal degeneration (FTD) compared to previously published data for Alzheimer disease (AD). <h3>Methods:</h3> A 250-item internet survey was administered primary caregivers patients with behavioral-variant FTD (bvFTD), progressive aphasia, motor neuron disease, corticobasal syndrome, or supranuclear palsy. The included validated scales staging, behavior, activities daily living, caregiver burden, and health economics, as...
Objective: The objective of this study was to evaluate the association patient satisfaction with type practitioner attending visits in primary care practice a managed organization (MCO). Study Design: We conducted retrospective observational 41,209 surveys randomly sampled from provided by pediatrics and adult medicine departments 1997 2000. Logistic regression, fixed effects, versus dissatisfaction estimated for each 3 scales: interaction, access, overall experience. Models were separately...
Regorafenib is a standard-care option for treatment-refractory metastatic colorectal cancer that increases median overall survival by 6 weeks compared with placebo. Given this small incremental clinical benefit, we evaluated the cost-effectiveness of regorafenib in third-line setting patients from US payer perspective.We developed Markov model to compare cost and effectiveness those placebo treatment cancer. Health outcomes were measured life-years quality-adjusted (QALYs). Drug costs based...
Despite a significant survival advantage of kidney transplantation compared with dialysis, nearly one third end-stage renal disease (ESRD) patients are not educated about as treatment option at the time ESRD diagnosis. Access to individualized, evidence-based prognostic information is needed facilitate and encourage shared decision making clinical implications whether pursue or long-term dialysis.We used national cohort incident in US Renal Data System surveillance registry from 2005 2011...
BACKGROUND Lung cancer screening recommendations are based on results from the National Screening Trial (NLST). The authors determined how screening‐eligible US population differs NLST participants in terms of characteristics that affect their ability to benefit screening. METHODS identified respondents 2012 Health and Retirement Study (HRS), a national survey individuals aged ≥50 years who eligible for Preventive Services Task Force Centers Medicare Medicaid criteria. Comorbidities, life...
Measuring the impact of drug resistance is an important step in understanding scope problem and formulating policies to limit emergence spread resistant organisms. Studies have focused on measuring increased costs, morbidity, mortality patients with infections due versus susceptible These generally found that worsens outcomes. By focusing only infected patients, however, they may understate resistance. It recognize also affects treatment individuals nonresistant In areas high rates...